Francesca Colapietro

I was walking in Barcelona to my hospital and saw a fantastic young crow attending the EASL School on interpretation of liver biopsy for hepatologists. Thanks to Xavi Forns and Alba Diaz for organizing it !! #barcelonaeasl #livertwitter @EASLedu @EASLnews

1/🚀JHEP Journal Club🚀 🤔What factors determine the risk of HCC in👫with autoimmune hepatitis (AIH)❓ 🔓pubmed.ncbi.nlm.nih.gov/37802188/ AIH 👉rare chronic liver disease 👉unclear etiology @analleo & the Int AIH Group🔍 1428 🌍patients 👇👇👇 #livertwitter

🚀 The mission of @ERN_RARE_LIVER is to improve the care of rare liver disease patients throughout Europe. 🎗️ To support Rare Disease Day we also share the stories of our patients, such as our #ERNYouthPanel Series on YouTube: lnkd.in/eMNw56sK 🔗 rare-liver.eu

@CcaEns @CharityAMMF @curecc

🆕Article in press❕ Incidence and predictors of #hepatocellularcarcinoma in patients with #autoimmunehepatitis Read it here👉bit.ly/46JfrlY #LiverTwitter

📣Check out our new paper on @AGA_CGH about potential role of #chatGPT 💬 as counselling tool for #NAFLD/#MASLD patients! 🎯 @AghemoAlessio @GiadaSebastiani @VWSWong @schattenbergJ @mromerogomez @lucavalenti75 @salvatore_petta @penny_manousou @lmiele74 cghjournal.org/article/S1542-…

Grazie ad AISF per l’opportunità di presentare questi dati, frutto dell’impegno dei colleghi membri dell’ IAIHG, che ringrazio ancora e sempre

📢HEAL study❗️ Weekly #albumin infusion in individuals with #cirrhosis improved ✅quality of life ✅endothelial dysfunction ✅inflammation ➡️albumin levels & cognitive benefit persisted after ending infusions Read it here👉bit.ly/3dwDxut @JasmohanBajaj #LiverTwitter

@AlessioGerussi giving a practical lecture of #DILI in #Immunotherapy at annual meeting... "to biopsy or to treat" @AisfFegato #HCC #LiverTwitter

📢HEAL study❗️ Weekly #albumin infusion in individuals with #cirrhosis improved ✅quality of life ✅endothelial dysfunction ✅inflammation ➡️albumin levels & cognitive benefit persisted after ending infusions Read it here👉bit.ly/3dwDxut @JasmohanBajaj #LiverTwitter

🆕Article in press❕ #HepatocellularCarcinoma risk in patients with chronic #hepatitisB receiving #tenofovir-🆚 #entecavir-based regimens: Individual patient data meta-analysis 🔓#OpenAccess at👉bit.ly/3WtYJBr #LiverTwitter

#KarolinskaInstitutet and snow

🆕EXPERT OPINION Treatment of #portalhypertension in patients with #HCC at the era of #Baveno VII By Dominique Thabut & Masatoshi Kudo Read it here👉bit.ly/3ilqP3A @BrainLIverPS @BavenoVII #LiverTwitter

📢Don't miss our next Webinar❗️ ✅The new EASL Clinical Practice Guidelines on sclerosing cholangitis 📅29 November 2022, 18:00 CET Register here: bit.ly/3VjozrL #LiverTwitter #MedTwitter #ERNRARELIVER #sharecarecure #sharingexpertise

🟪NEW Article in press❕ Long-term results of #MycophenolateMofetil 🆚 #azathioprine use in patients with #AutoimmuneHepatitis 🔓#OpenAccess at👉bit.ly/3Rqojor #LiverTwitter

What does the future hold for #PBC therapies? Find out today with #EASLStudio! 🔗 easl.eu/easl-studio-ep… #Livertwitter #PBCDay2022 @EASLEdu @EASLEUaffairs @GSK @IpsenGroup @CymaBay @AutoimmuneLiver @AnaLleo @PBCFoundation @PBCRobert @PBCers @GlobalLiver

🟪NEW Article in press❕ Quantitative magnetic resonance #cholangiopancreatography metrics are associated with disease severity and outcomes in patients with #PrimarySclerosingCholangitis 🔓#OpenAccess at👉bit.ly/3CWKv64 #LiverTwitter

🔥FDA approves durvalumab for locally advanced or metastatic biliary tract cancer🔥 👉great news for our patients👏👏 👉waiting for EMA... again .... @myESMO @EASLedu @OncoAlert #livertwitter #cholangiocarcinoma @CcaEns #Immunotherapy

I wish to congratulate @Alexfornergon @AghemoAlessio and @lucavalenti75 with the new (and substantially higher) impact factor of @LiverInt 8.754 ✅ This team makes a difference for the #livertwitter field 🙏 for the great work @wileyhealth 👉 Congratulations @ReibergerThomas

Proud to share data📊 on our latest study on incidence and predictors of HCC in a large and multicentric AIH cohort! #ILC2022